Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share

v3.7.0.1
Net Loss Per Share
6 Months Ended
Jun. 30, 2017
Earnings Per Share [Abstract]  
Net Loss Per Share

10. Net Loss Per Share


Basic and diluted net loss per common share is calculated by dividing net loss applicable to Heat Biologics, Inc. by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company’s potentially dilutive shares, which include outstanding stock options and warrants, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. The following table reconciles net loss to net loss attributable to Heat Biologics, Inc.:


 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

2017

 

2016

 

 

2017

 

 

2016

 

Net loss

 

$

(3,309,081

)

$

(3,032,767

)

 

$

(6,549,809

)

 

$

(7,767,253

)

Net loss: Non-controlling interest

 

 

(90,166

)

 

(107,546

)

 

 

(140,956

)

 

 

(282,428

)

Net loss attributable to Heat Biologics, Inc.

 

$

(3,218,915

)

$

(2,925,221

)

 

$

(6,408,853

)

 

$

(7,484,825

)

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

  

Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.—basic and diluted

 

 

35,244,833

 

 

17,524,641

 

 

 

31,124,119

 

 

 

13,324,641

 

Net loss per share attributable to Heat Biologics, Inc.—basic and diluted

 

$

(0.09

)

$

(0.17

)

 

$

(0.21

)

 

$

(0.56

)


The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:


 

 

For the Six Months Ended

June 30,

 

 

 

2017

 

2016

 

Outstanding stock options

 

 

2,520,000

 

 

1,574,484

 

Outstanding restricted stock units

 

 

302,625

 

 

 

Outstanding common stock warrants

 

 

3,103,963

 

 

6,967,382